Teriparatide in the treatment of osteoporosis.

Simple item page
dc.contributor.authorStroup, Jeffrey ++
dc.contributor.authorKane, Michael P
dc.contributor.authorAbu-Baker, Asim M ++
dc.date.accessioned2023-11-21T20:17:16Z
dc.date.available2023-11-21T20:17:16Z
dc.date.issued3/15/2008
dc.descriptionClick on the Resource Link to access the article (may not be free).
dc.description.abstractPurpose: The efficacy, safety, and cost of teriparatide in the treatment of osteoporosis are reviewed. Summary: Osteoporosis is a leading cause of fractures in women and men but is underdiagnosed and undertreated. Antiresorptive therapies (calcitonin, estrogen, bisphosphonates, and selective estrogen-receptor modulators) have historically been used to treat this condition. Teriparatide (recombinant human parathyroid hormone) is an anabolic agent labeled for use in postmenopausal women and men with osteoporosis who are at high risk for fractures. Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density. Teriparatide is expensive but may be cost-effective in selected patients. Conclusion: Teriparatide offers a therapeutic option for patients at high risk of an osteoporotic fracture and for patients who are intolerant of or unresponsive to antiresorptive therapy.
dc.description.urihttps://doi.org/10.2146/ajhp070171
dc.identifier.citationStroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9. doi: 10.2146/ajhp070171. PMID: 18319498.
dc.identifier.issn1079-2082
dc.identifier.other18319498
dc.identifier.urihttps://hdl.handle.net/20.500.14303/398
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofAmerican Journal of Health-System Pharmacy : AJHP
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectBone Density Conservation Agents / therapeutic use
dc.subjectFractures, Bone / prevention & control
dc.subjectOsteoporosis / drug therapy
dc.subjectTeriparatide / therapeutic use
dc.titleTeriparatide in the treatment of osteoporosis.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Kane, Michael Publications
Pharmacy Resident Publications